Table formulation studies on nimesulide and meloxicam-cyclodextrin binary systems

AAPS PharmSciTech

Volumn 8, Issue 2, 2007, Pages

  Nalluri, Buchi N ^a,c   Chowdary, K P R ^a   Murthy, K V R ^a   Becket, G ^b   Crooks, Peter A ^c  

^a ANDHRA UNIVERSITY   (India)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c University of Kentucky   (United States)

Author keywords

Cyclodextrins; Dissolution properties; Meloxicam; Nimesulide; Stability studies; Tablet formulation

Indexed keywords

BETA CYCLODEXTRIN; GAMMA CYCLODEXTRIN; MELOXICAM; NIMESULIDE; BETA CYCLODEXTRIN DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; GAMMA-CYCLODEXTRIN; SULFONAMIDE; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG FORMULATION; DRUG GRANULATION; DRUG MIXTURE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; EVAPORATION; HUMIDITY; IN VITRO STUDY; SHELF LIFE; TABLET COMPRESSION; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS; TABLET MANUFACTURE; TEMPERATURE; CHEMISTRY; SOLUBILITY; TABLET;

BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; GAMMA-CYCLODEXTRINS; SOLUBILITY; SULFONAMIDES; TABLETS; THIAZINES; THIAZOLES;

EID: 34249742727     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Duchene D, Wouessidjewe D. Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev Ind Pharm. 1990;16:2487-2499.
2. Bekers O, Uijtendal EV, Beijnen JH, Bult A, Underberg WJ. Cyclodextrins in pharmaceutical field. Drug Dev Ind Pharm. 1991;17:1503-1549.
3. Davis R, Brogden RN. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs. 1994;48:431-454.
4. Engelhardt G, Homma D, Schlegel K, Schnitzeler C, Utzmann R. Anti inflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal anti inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995;44:423-433.
5. Engelhardt G, Bogel R, Schnitzeler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part 1: in vitro findings. Biochem Pharmacol. 1996;51:21-28.
6. Churchill L, Graham AG, Shih CK, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology. 1996;4:125-135.
7. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting J, Botting R, eds. Improved Nonsteroidal Anti-inflammatory Drugs- COX-2 Enzyme Inhibitors. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1996:103-119.
8. Distel M, Mueller C, Bluhmki E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology. 1996;4: 71-81.
9. Turck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung. 1997;47:253-258.
10. Piel G, Pirotte B, Delneuveille I, et al. Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes. J Pharm Sci. 1997;86:475-480.
11. Nalluri BN, Chowdary KPR, Murthy KV, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS PharmSciTech. 2003;4:E2. serial online.
12. Naidu NB, Chowdary KP, Murthy KV, Satyanarayana V, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J Pharm Biomed Anal. 2004;35:75-86.
13. Bodmeier R, Paerataku O. Constant potassium chloride release from microporous membrane-coated tablets prepared with aqueous colloidal polymer dispersions. Pharm Res. 1991;8: 355-359.
14. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48-49.
15. Carstensen JT. Stability and dating of solid dosage forms. In: Carstensen JT, ed. Pharmaceutics of Solids and Solid Dosage Forms. New York, NY: Wiley-Interscience; 1997:182-185.